Benzinga | Aug 18, 2020 09:06AM EDT

AIkido Pharma Sponsors Survival Study Of University Of Kentucky Anticancer Drug G4-1 In Exchange For Exclusive Option To License

NEW YORK, Aug. 18, 2020 /PRNewswire/ --AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced that it will provide funding for a 30-day survival study in mice in collaboration with University of Kentucky related to the anticancer drug designated G4-1, a novel proteasome inhibitor. In exchange, Aikido has been granted an exclusive option to license the drug ("Option") pending the results of the study.